Back

Cross-sectional analysis of demographic and clinical characteristics of patients using icosapent ethyl

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor John R Nelson

California Cardiovascular Institute, Fresno (United States of America)

5 More presentations in this session

Presentation thumbnail
Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study
Professor S. Yamashita (Izumisano, JP)
Abstract Slides Video
Presentation thumbnail
Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations
Miss D. Dunca (London, GB)
Abstract Slides Video
Presentation thumbnail
RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys
Professor L. Gan (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation
Doctor L. Michael (Indianapolis, US)
Abstract Slides Video
Presentation thumbnail
Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome
Doctor A. Nakamura (Morioka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Where are we now? Decision-making in LDL-C lowering and CV risk
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Congress Presentation
What’s new on lipid-lowering drugs: from statins to gene editing and beyond

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources